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these to clinical factors. Here we summarize the major
findings resulting from the explosion of knowledge
from molecular studies of lung cancer, and we attempt
to provide some insight as to how these findings may
affect clinical practice in the future. All of these efforts
are predicated on continued efforts in preventing smok-
ing initiation and assisting in smoking cessation. They
also need to be coupled to recent advances in computed
tomography–guided screening for early diagnosis.
Molecular alterations in lung cancer cells (Table I)
Markers of genetic instability. Lung cancer is the
end stage of multiple-step carcinogenesis, in most cases
driven by genetic and epigenetic damage caused by
chronic exposure to tobacco smoke carcinogens. The
genetic instability in human cancers appears to exist at
two levels: at the chromosomal level, including large-
scale losses and gains, and at the nucleotide level,
A lthough much is known about the causes and clini-cal features of lung cancer, including outcome
according to TNM stages and histologic features, only
recently have physicians been able to delve into the
molecular basis of lung cancer pathogenesis and relate
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including single or several base changes.1 Lung cancers
harbor many numeric chromosome abnormalities (an-
euploidy) and structural cytogenetic abnormalities
including deletions and nonreciprocal translocations.
Chromosomal instability leading to aneuploidy is asso-
ciated with the loss of function of a mitotic checkpoint.
Exactly how this loss comes about in lung cancer is not
known. Tumor DNA copy number aberrations can be
more finely mapped by means of newer molecular
cytogenetic techniques such as comparative genomic
hybridization, which also demonstrated multiple abnor-
malities in lung cancer.2,3
At least three classes of cellular genes are involved:
proto-oncogenes, tumor suppressor genes (TSGs), and
DNA repair genes. Oncogenic activation often occurs
via point mutation, gene amplification, or rearrange-
ment, whereas TSGs are classically inactivated by loss
of one parental allele combined with a point or small
mutation, or methylation inactivation of a target TSG in
the remaining allele. Additionally, dysregulated gene
expression (either increased or decreased expression)
can occur by other, as yet unknown, mechanisms.
Current studies have not yet confirmed a prominent
role for abnormalities of DNA repair genes in lung can-
cer including DNA mismatch repair genes; however,
alterations in simple repeat sequences are seen. The
phenotype seen in lung cancers appears different from
the typical replication error repair (RER+) phenotype
seen in tumors with mutations in DNA mismatch repair
genes. In lung cancer the instability affects a relatively
smaller proportion of markers and causes a single
“shift” of individual allelic bands in contrast to “RER+
laddering.” We thus refer to the phenotype seen in lung
cancer as “microsatellite alteration.” Microsatellite alter-
ation frequencies have been reported in approximately
35% of small cell lung cancers (SCLCs) and 22% of
non–small cell lung cancers (NSCLCs)4 and have been
reported to be associated with younger age,5 reduced
survival,6 and advanced tumor stage.6,7 There are reports
implicating other DNA repair pathways in lung cancer.
These include occasional mutations in a gene involved in
the repair of oxidative DNA damage (OGG1)8 and inac-
tivation of the DNA repair gene O6-methylguanine-
DNA methyltransferase (MGMT) by the epigenetic
mechanism of promoter hypermethylation.9
Specific molecular alterations in lung cancer cells
Growth stimulation and oncogenes. Autocrine and
paracrine growth stimulatory loops exist in lung can-
cers as a consequence of the expression of growth fac-
tors, regulatory peptides, and their receptors by either
the cancerous or adjacent normal cells. Several but not
all components of these stimulatory pathways are
proto-oncogene products.
Gastrin-releasing peptide (GRP)/bombesin (BN)
autocrine loop. GRP is the 27 amino acid mammalian
homologue of the amphibian peptide BN. GRP/BN
functions include a role in lung development and
Table I. Major molecular alterations in lung cancer
SCLC NSCLC
Putative autocrine loops GRP/GRP receptor HGF/MET
SCF/KIT NDF/ERBB
RAS mutation <1% 15%-20%
MYC amplification* 15%-30% 5%-10%
p53 mutation (with 17p13 LOH) 75%-100% ~50%
Abnormal p53 expression (IHC) 40%-70% 40%-60%
Absent RB expression (with 13q14 LOH) ~90% 15%-30%
p16 mutation (with 9p21 LOH) <1% 10%-40%
Absent p16 expression (IHC) 0%-10% 30%-70%
3p LOH various markers 100% 90%
4p LOH 50% ~20%
4q LOH 80% 30%
8p21-23 80%-90% 80%-100%
BCL-2 expression 75%-95% 10%-35%
Telomerase activity ~100% 80%-85%
Microsatellite instability ~35% ~22%
Promoter hypermethylation Not studied 10%-40% various genes†
GRP, Gastrin-releasing peptide; HGF, hepatocyte growth factor; MET, MET proto-oncogene; SCF, stem cell factor; KIT, KIT proto-oncogene; NDF, neu differentia-
tion factor; ERBB, neuregulin receptor; LOH, loss of heterozygosity; IHC, immunohistochemistry; BCL-2, BCL-2 anti-apoptotic proto-oncogene.
*Overexpression without amplification is observed in other cases. SCLC amplifications include MYC, MYCN, and MYCL.
†p16, death-associated protein (DAP) kinase, glutathione S transferase P1 (GSTP1), and O6-methylguanine-DNA methyltransferase (MGMT).
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repair.10 Immunohistochemical studies show that
approximately 20% to 60% of SCLC cancers express
GRP/BN, whereas non-SCLC (NSCLC) express
GRP/BN less frequently.11 The human GRP/BN recep-
tor subtypes belong to the G-protein–coupled receptor
superfamily and include GRP-, neuromedin B–, and
BN subtype–3 receptors; all of these can be expressed
in SCLC, NSCLC, and in some biopsy specimens of
bronchial epithelium of smokers.12,13 However, lung
cancers so far have not been found to have mutations of
either GRP/BN or the GRP/BN receptor; thus the
mechanisms for “reactivation” of these embryonic reg-
ulatory loops are yet unidentified. The GRP/BN
autocrine loop is an important growth stimulatory loop
in lung cancer, particularly SCLC. The in vitro forma-
tion of soft agar clones and the in vivo growth of nude
mouse xenografts of SCLC cell lines are inhibited by a
neutralizing monoclonal antibody directed against
GRP/BN, as well as by antagonists of BN.14,15 A clini-
cal trial of the anti-BN monoclonal antibody has shown
some antitumor activity in previously treated patients
with SCLC.16 This system appears to play an early role
in pathogenesis, since there is an increased likelihood
of expression of the GRP receptor messenger RNA in
the respiratory epithelium of some individuals with a
history of prolonged tobacco exposure, and expression
of the GRP receptor mRNA is accompanied by respon-
siveness of these respiratory epithelial cells in vitro to
the mitogenic effects of BN-like peptides.13 These
effects also appear to persist after smoking cessation.
ERBB family. NSCLCs but not SCLCs often demon-
strate abnormalities of the neuregulin receptors ERBB2
and ERBB1, a family of transmembrane receptor tyro-
sine kinases. On ligand binding, ERBB receptors
homodimerize or heterodimerize, thereby inducing
intrinsic kinase activities that initiate intracellular sig-
nal transduction cascades including the MAP kinase
pathway. ERBB2 (HER2/neu) is highly expressed in
approximately 30% of NSCLCs, especially adenocar-
cinomas.17,18 Transfection experiments suggest that
ERBB2 overexpression contributes to tumorigenicity in
immortalized human bronchial epithelial cells.19 An
anti-ERBB2 monoclonal antibody inhibited the in vitro
growth of ERBB2 expressing NSCLC cell lines.20
High ERBB2 levels are associated with the multiple
drug resistance phenotype21 and increased metastatic
potential in NSCLC,22 which may help explain the
poor clinical outcome linked to ERBB2 overexpression
reported by some investigators.23,24 Monoclonal anti-
bodies against the ERBB2 receptor (Herceptin) have
entered clinical trials combined with chemotherapy in
both breast cancer and lung cancer.
ERBB1 (epidermal growth factor receptor) regulates
epithelial proliferation and differentiation and is usual-
ly activated in lung cancer cells by overexpression by
an unknown mechanism. The production of ERBB1
ligands such as epidermal growth factor and transform-
ing growth factor b by lung cancer cells expressing
cognate receptors indicates an autocrine loop.18,25
More common in NSCLC, ERBB1 activation may be
related to tumor stage and differentiation.26,27 Mono-
clonal antibodies against the ERBB1 receptor (C225,
ImClone Systems Incorporated, New York, NY) are
entering clinical trials combined with chemotherapy. In
addition, several tyrosine kinase inhibitors that have
some selectivity as epidermal growth factor receptor
(ERBB1) blockers (CP358774, ZD1839) are also
entering clinical trials.
Other membrane tyrosine kinases. Hepatocyte
growth factor stimulates epithelial cells to proliferate,
move, and undergo complex differentiation programs.
During fetal lung development, hepatocyte growth fac-
tor acts as a mesenchyme-derived morphogenic fac-
tor.28 The constitutively low levels of hepatocyte
growth factor increase in response to lung or distant
injury.29 Hepatocyte growth factor stimulates mitogen-
esis and/or motogenesis of human bronchial epithelial,
alveolar type II, and SCLC cells in vitro. The receptor
for hepatocyte growth factor is the MET proto-onco-
gene; it is generally expressed in normal lung and both
SCLC and NSCLC; hepatocyte growth factor, howev-
er, is expressed mostly in NSCLCs, suggesting an
autocrine loop specific for NSCLC.30,31 Clinically, high
hepatocyte growth factor levels were associated with a
poor outcome in patients with resectable NSCLC.32
The KIT proto-oncogene encodes the tyrosine kinase
receptor, CD117. It is co-expressed together with its
ligand, stem cell factor, in many SCLCs,33,34 represent-
ing another autocrine loop that may provide a growth
advantage or mediate chemo-attraction. Other putative
loops involve insulin-like growth factor 1, insulin-like
growth factor 2, and the type I insulin-like growth fac-
tor receptor, which are frequently co-expressed in both
SCLC and NSCLC,35 as well as platelet-derived
growth factor and its receptor.36
Nicotine and opioid receptors. Lung cancer cells
express nicotine receptors and a variety of opioid re-
ceptors, as well as being able to produce several opioid
peptides.37 Intriguingly, opioids can inhibit lung cancer
cell growth and cause apoptosis.38 This leads to the
apparent paradox whereby lung cancer cells express a
negative opioid autocrine regulatory loop. Regardless,
nicotine acting through specific, high-affinity, nicotinic
acetylcholine receptors on lung cancer cells can antag-
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onize the apoptotic effect of opioids. Thus it is possible
that inhaled nicotine from smoking may play a role in
lung cancer pathogenesis by inhibiting apoptosis, for
example, in precursor lesions.38
RAS. The RAS proto-oncogene family (KRAS, HRAS,
and NRAS) encodes plasma membrane proteins and is
activated in some lung cancers by point mutations, and
RAS mutations result in inappropriate prolonged sig-
naling for continued cell division. KRAS is the most
frequently activated RAS gene in lung cancer, usually
by mutations at codon 12 but occasionally codons 13
and 61. KRAS mutations affect approximately 20% to
30% of lung adenocarcinomas and 15% to 20% of all
NSCLC but rarely SCLCs.11 There is subtype hetero-
geneity; for example, KRAS mutations are present in
parenchymal but not bronchial adenocarcinomas,39 and
goblet-cell subtypes of adenocarcinoma have the high-
est frequency of KRAS mutations.40 KRAS mutations
correlate with smoking41 and most mutations comprise
the G-T transversions expected from bulky DNA
adducts caused by the polycyclic hydrocarbons and
nitrosamines in tobacco smoke.42 The presence of
KRAS mutations in a patient’s tumor appears to portend
a poor prognosis in NSCLC, although this is debat-
ed.13,43-46 However, KRAS mutations were not associated
with in vitro resistance against a range of chemothera-
peutic agents in NSCLC cell lines.47 Moreover, neither
chemotherapy sensitivity nor survival correlated with
KRAS mutations in a prospective study of advanced
lung adenocarcinoma.48 To be active in the cell, RAS
has to have a lipid modification (farnesylation) regulat-
ed by an enzyme (farnesyltransferase). Several farne-
syltransferase inhibitors (from Bristol Myers Squibb,
Janssen, and Merck) are currently in clinical trials
against lung cancer.
MYC. RAS signaling ultimately activates nuclear
proto-oncogene products like MYC, which on het-
erodimerization transcriptionally activates downstream
genes, which drives cells to grow. The myc family com-
prises MYC, MYCN, and MYCL (originally isolated
from a lung cancer49). MYC is the most frequently acti-
vated and affects SCLC and NSCLC, whereas the oth-
ers usually only affect SCLC. Activation occurs by
gene amplification (~20-115 copies per cell) or by tran-
scriptional dysregulation, both of which lead to protein
overexpression. Richardson and Johnson11 concluded
from 17 studies that 18% to 31% of SCLCs had ampli-
fication of one MYC family member. Conversely, only
8% to 20% of NSCLCs were affected. MYC amplifica-
tion appears to occur more frequently in chemotherapy-
treated patients and the “variant” SCLC subtype50 and
may correlate with adverse survival. Last, in vitro
growth inhibition of an SCLC cell line by all-trans-
retinoic acid was associated with increased neuroen-
docrine differentiation, increased MYCL, and de-
creased MYC expression.51
Tumor suppressor genes (TSGs)
p53. p53 maintains genomic integrity in the face of
DNA damage from g or ultraviolet irradiation and car-
cinogens. DNA damage or hypoxia results in a rapid
increase of p53, which acts as a sequence-specific tran-
scription factor regulating downstream genes including
p21, MDM2, GADD45, and BAX, thereby helping to
regulate the G1/S cell cycle transition, G2/M DNA
damage checkpoint, and apoptosis. Dysfunction of p53
allows the inappropriate survival of genetically dam-
aged cells, setting the stage for the accumulation of
multiple mutations and the subsequent evolution of a
cancer cell. p53 plays a critical role in lung cancer; its
chromosome 17p13 locus is frequently hemizygously
deleted, and mutational inactivation of the remaining
allele occurs in 75% or more of SCLCs and about 50%
of NSCLCs.42,52,53 p53 mutations in lung tumors corre-
late with cigarette smoking and are mostly the G-T
transversions expected of tobacco smoke carcino-
gens.42 Furthermore, benzo(a)pyrene, a major tobacco
smoke carcinogen, selectively forms adducts at the
major p53 mutational hot spots in bronchial epithelial
cells.54 Missense p53 mutations can prolong the protein
half-life, leading to easily detected mutant p53 protein
by immunohistochemical studies.55 However, other
types of p53 mutations do not correlate with immuno-
histochemical staining. Studies have shown abnormal
p53 expression by immunohistochemistry in 40% to
70% of SCLCs and 40% to 60% of NSCLCs (squa-
mous cell carcinomas higher than adenocarcino-
mas).56-58 Although the prognostic value of p53
immunohistochemistry or mutational abnormalities is
controversial,59 mutations have been linked to response
to cisplatin-based chemotherapy in NSCLC60 and
response to radiotherapy.61
Can a mutant p53 be replaced with a normal wild-
type copy with beneficial effect? The in vitro reintro-
duction of wild-type p53 into lung cancer cells that also
have various other genetic abnormalities besides p53
blocks tumor cell growth by inducing apoptosis.62
Direct injection, using a retroviral vector containing
wild-type p53, into tumors (either by bronchoscopy or
by a computed tomography–guided needle) in 9
patients with NSCLC in whom conventional treatment
had failed led to tumor regression in a third of
patients.63 Other promising alternative strategies for
delivering p53 as gene replacement therapy include
liposomal-p53 complexes delivered endobronchially
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and adenovirus-mediated p53 transfer given locally,
endobronchially, or even systemically.64
Antibodies against the p53 protein develop in some
15% to 25% of patients with lung cancer, indicating
that mutant p53 protein overexpression can lead to a
humoral immune response. Whereas the development
of p53 antibodies appears associated with squamous
histology, the value of the antibodies as diagnostic or
prognostic markers is controversial.65-68 Nonetheless,
p53 antibodies appear to be reduced during chemother-
apy.69 DNA from tumor cells can be released into
patients’ plasma. Thus additional future early detection
strategies may involve screening by means of poly-
merase chain reaction technology for the presence of
DNA in patient plasma that contains mutant p53
sequences.70
There are other proteins homologous to p53, includ-
ing p51 at chromosome loci 3q28 and p73 at lp36, both
of which can induce growth suppression and apoptosis.
Mutations of p51 appear to be infrequent in lung can-
cer.71 Similarly, p73 mutations are absent or infrequent
in lung cancers despite frequent allele loss of the 1p36
region (42%).72,73 In fact, it may be that p73 “activa-
tion” is important since wild-type p73 is highly
expressed in lung tumors.74
p21 is a p53-responsive gene that inhibits cyclin/
cyclin-dependent kinase (CDK) complexes at the G1
phase. Although not somatically mutated in lung can-
cer, p21 was overexpressed in 65% to 75% of NSCLCs,
especially in well-differentiated tumors.75 One NSCLC
study reported that p21 expression was linked to a
favorable outcome,76 whereas another suggested that
concordant expression of p21 and transforming growth
factor b 1 predicts better survival than discordant
expression.77
The MDM2 oncogene product inhibits p53 function
by blocking its regulation of target genes and also
enhances proteasome-dependent degradation of p53.
Conversely, p53 regulates (increases) the expression of
MDM2 by directly binding and activating the MDM2
promoter. The MDM2 protein is overexpressed in 25%
of NSCLCs,78 and MDM2 expression without abnor-
mal p53 expression (mutation) has been reported to be
a favorable prognostic factor. Thus different ways of
inactivating the p53 pathway may have different clini-
cal outcomes.
p16-cyclin D1-CDK4-RB pathway
The retinoblastoma gene, RB. The pl6-cyclin D1-
CDK4-RB pathway is central to controlling the G1-S
transition of the cell cycle, and its components are
functionally altered or mutated in many cancers. The
major growth suppressing function of RB is by block-
ing G1-S progression. Inactivation of both RB alleles at
chromosome region l3ql4 is common in lung cancers,79
with protein abnormalities detected in about 90% of
SCLCs and 15% to 30% of NSCLCs.58,80-82 Functional
RB loss can include deletion, nonsense mutations, or
splicing abnormalities, frequently leading to a truncat-
ed RB protein. Whether absent RB expression is asso-
ciated with poor prognosis in NSCLCs is controver-
sial.58,82-84 Functionally, in vitro reintroduction into
tumor cells of a wild-type RB suppresses SCLC
growth.85 The inherited germline form of mutant RB is
associated with the development of the childhood dis-
ease retinoblastoma, and relatives of retinoblastoma
patients carrying germline RB mutation are about 15
times more likely to die of lung cancer than the gener-
al population.86 Thus in this rare inherited disorder
there appears to be an example of genetic predisposi-
tion to lung cancer. Two RB-related genes also have
been implicated in lung cancer including, p107 and
pRB2/p130, where decreased expression of these pro-
teins is associated with more aggressive histologic
behavior.87
Cyclin D1 and CDK4. Cyclin D1 inhibits the activi-
ty of RB by stimulating its phosphorylation by CDK4.
Thus cyclin D1 overexpression is an alternative mech-
anism to RB mutation for disrupting the pl6-cyclin D1-
CDK4-RB pathway. Cyclin D1 was overexpressed in
25% to 47% of primary NSCLCs and in some cases has
been associated with poor prognosis.88-90 Transfection
of a cyclin D1 antisense construct into lung cancer cell
lines (and thus inhibiting any tumor-related cyclin D1
production) induces destabilization of RB and retards
growth.91 Although amplification of CDK4 has been
reported in other human malignancies, its role in lung
cancer has not yet been studied. However, a CDK
inhibitor, flavopiridol, is in clinical trials against lung
and other cancers.
p16. Chromosome 9p allele loss is observed in many
lung cancers.92 p16 (p16INK4 CDKN2) is situated at
9p21 and frequently undergoes allele loss and mutation
in lung cancer.4 As p16 regulates RB function by
inhibiting CDK4 and CDK6 kinase activity, p16 inacti-
vation is thus another tumor strategy for disrupting the
pl6-cyclin D1-CDK4-RB cell cycle control pathway.
p16 abnormalities are frequent in NSCLC but rare in
SCLC (where the pathway is usually disrupted by an
RB mutation). Homozygous deletion or point muta-
tions occur in 10% to 40% of NSCLCs.93,94
Hypermethylation in the 5´ CpG island of the retained
allele may also cause loss of expression of pl6 from the
remaining allele in lung cancer.95,96 These mechanisms
contribute to the loss of p16 expression in NSCLC,
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functionally analogous to the preferential RB inactiva-
tion in SCLC, with the common end result of pl6-cyclin
D1-CDK4-RB pathway disruption.84,97-101 Co-inactiva-
tion of RB and p16 in any one tumor is rare, but cyclin
D1 overexpression can coexist with these abnormalities
in the same tumor.102 Notably, 10% to 30% of NSCLCs
appear normal for RB and p16, indicating involvement
of cyclin D1, CDK4, or other pathway members in
these cases. Perhaps 30% to 50% of early-stage prima-
ry NSCLCs do not express p16. p16 alteration and loss
of function in lung cancer may be associated with
tumor progression, clinical stage, and survival,
although not all studies concur.58,84,101,103,104
p19ARF. The p16 locus also encodes a second alterna-
tive reading frame protein, p19ARF, that overlaps with
p16. The amino acid sequence of these two alternative-
ly spliced messages are different. However, they both
appear to be important in growth regulation. p19ARF
binds to the MDM2-p53 complex and prevents p53
degradation, resulting in p53 activation. Immuno-
histochemical analysis suggests that the p19ARF protein
expression was more frequently lost in tumors with
neuroendocrine features.105 Thus one genetic locus at
9p21 produces two products, p16 and p19ARF, both of
which play a critical role in growth regulation: p16 with
the RB pathway and p19ARF with the p53 pathway.
Reduced expression of another CDK inhibitor gene,
p27KIP1, was correlated with poor prognosis in
NSCLC.106,107 In contrast, most SCLCs exhibit in-
creased p27KIP1 staining, suggesting a possible link with
neuronal differentiation.107 p57KIP2 at chromosome
region 11p15 is imprinted with maternal expression and
p57KIP2 expression is down-regulated by selective loss
of the maternal alleles in some lung cancers.108
Other candidate TSGs. Cytogenetics and allelotyping
have revealed many hemizygous and some homozy-
gous deletions at multiple chromosomal regions in lung
cancers. In the classic TSG paradigm, the presence of
underlying TSGs is suggested as the target of these
genetic losses. The chromosomal regions showing
hemizygous deletions include 1p, 1q, 2q, 3p, 4p, 4q, 5q,
6p, 6q, 8p, 8q, 11p, 11q, 14q, 17q, 18q, and 22q.109-118
Although several of these chromosomal arms contain
known or candidate TSGs (such as APC at 5q21, WT1
at 11p13, and NF2 at 22q12), these genes are not
known to be mutated in lung cancer.
Very frequent hemizygous loss of one chromosome
3p allele occurs in lung cancer,119 implicating multiple
TSGs in at least three regions including 3p25-26,
3p21.3-22, and 3p14-cen.120 Moreover, five separate
homozygously deleted regions at 3p12-13, 3p14.2, and
3p21 occur in several lung cancer cell lines.4 One can-
didate is FHIT at 3p14.2, which undergoes frequent
hemizygous and occasional homozygous deletion in
lung cancer cells and encodes a dinucleoside hydro-
lase. Lung cancer cells frequently (40%-80%) express
abnormal mRNA transcripts of FHIT but nearly always
also express wild-type FHIT transcripts.121,122 How-
ever, unlike classic TSG inactivation, FHIT point muta-
tions are rare,121,122 and abnormal transcripts can be
found in normal lung tissue.123 Notwithstanding, Fhit is
expressed in normal lung but absent Fhit protein occurs
in primary lung tumors.124 Moreover, FHIT allele loss
is more common in smokers than nonsmokers125 and
may be associated with a poorer survival in NSCLC.126
Furthermore, reintroduction of exogenous wild-type
FHIT suppressed tumorigenicity of lung cancer cell
lines in nude mice,127,128 although others have reported
that FHIT transfection does not suppress tumor growth
of human cancer cell lines.129 The 3p21.3 region has
been extensively examined for putative TSGs,119 par-
ticularly at a 600-kb region homozygously deleted in
three SCLC cell lines,130,131 while another 800-kb dele-
tion region exists at 3p21.132
Protein tyrosine phosphatases may play a role in
tumor suppression because of their ability to antago-
nize the growth-promoting protein kinases. A candidate
is the phosphatase encoded by the PTEN gene at chro-
mosome 10q23.133 PTEN is mutated in a few primary
lung cancers, and several lung cancer cell lines show
homozygous deletions of this gene.134 Another candi-
date at 10q, region 25.3-26.1, is DBMT1, which is fre-
quently down-regulated and occasionally homozygous-
ly deleted in lung cancer.135
11q23-24 chromosome is a region containing fre-
quent allelic loss including 71.4% of lung cancer cell
lines, with two distinct minimal regions of loss.136 One
region contains the gene encoding the beta isoform of
the A subunit of the human protein phosphatase 2A
(PPP2R1B). Recently, mutations were described in
lung and colon cancers, suggesting that PPP2R1B
functions as a TSG.137
Apoptosis. Tumor cells often escape the physiologic
response (programmed cell death or apoptosis) to
cellular and DNA damage. Expression of the BCL-2
anti-apoptotic proto-oncogene is relatively higher in
squamous cell carcinoma (25%-35%) than in adeno-
carcinoma (~10%).138-141 It also correlates with neu-
roendocrine differentiation and is higher in SCLCs
(75%-95%) than in NSCLCs.138,142 The latter is inter-
esting inasmuch as SCLCs are more responsive to
chemotherapy, which usually results in tumor apopto-
sis. Clinically, there is a trend toward longer survival in
SCLCs that express BCL-2,142 but this relationship is
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controversial in NSCLC.139-141,143,144 BAX, which
counteracts BCL-2 and promotes apoptosis, is a down-
stream transcription target of p53. Expression of BAX
and BCL-2 are inversely related in neuroendocrine can-
cers; most typical and atypical carcinoids have low
BCL-2 and high BAX expression, with the reverse in
most SCLCs and large cell neuroendocrine cancers.56
There are multiple anti-apoptosis approaches that are in
preclinical development or in early clinical trials. These
include antisense BCL2 in SCLC (to inhibit the transla-
tion of BCL2 mRNA and down-regulate BCL2 protein
expression), BCL-xL antisense in NSCLC, and a bispe-
cific BCL2-BCLxL antisense to target both SCLC and
NSCLC.
The receptor Fas (CD95) and the Fas ligand (FasL)
also play key roles in the initiation of apoptotic path-
ways. FasL can induce apoptosis in activated T cells, a
mechanism thought to contribute to immune privilege
sites. Thus it is notable that lung cancer cell lines and
tumors express FasL, and co-culture of lung cancer
lines with a Fas-sensitive human T-cell line induces T-
cell apoptosis.145 Meanwhile, cell surface Fas expres-
sion has been shown to be reduced in adenocarcinomas,
which may also account for resistance to Fas-mediated
apoptosis.146 Thus it appears that lung cancers can make
FasL but cannot respond to it because they lack the
receptor, Fas. However, the FasL they produce can func-
tion to inactivate T cells, providing for a mechanism of
escape from a patient’s immune response.
Telomerase activity. Human telomeres are special-
ized structures located at the ends of chromosomes
comprising TTAGGG tandem repeats bound to specif-
ic proteins. During normal cell division, the absence of
telomerase activity is associated with progressive
telomere shortening, perhaps representing an intrinsic
“cellular clock,” leading to cell senescence and normal
cell “mortality.” In contrast, germ cells, some stem
cells, and most cancer cells have telomerase activity,
which is able to compensate for telomere shortening by
replacing the hexameric repeats, leading to potential
cellular “immortality.” The telomerase holoenzyme is
composed of both RNA and protein (enzymatic) sub-
units. Both of these components are required for activ-
ity and can be overexpressed in cancer, with the final
measure being telomerase enzyme activity. Nearly all
SCLCs and 80% to 85% of NSCLCs have high levels
of telomerase activity.147,148 High telomerase activity
was associated with increased cell proliferation rates
and advanced stage in NSCLCs.148 Additionally,
telomerase activity and/or dysregulated RNA expres-
sion are frequent in carcinoma in situ lesions, implicat-
ing involvement early in lung cancer development.149
Aberrant methylation. Methylation of the promoter
regions of genes is frequently used to regulate gene
expression with hypermethylation of the promoter
region, resulting in loss of expression. Abnormalities of
DNA methylation occur consistently in human neopla-
sia, and promoter region hypermethylation in 5´ CpG
islands may transcriptionally silence and thus inacti-
vate TSGs such as the RB, VHL, and p16 genes. In
NSCLCs, p16 hypermethylation contributes to down-
regulation of p16 expression and occurs at an early
stage in lung cancer development.95,96,150 A series of
genes have been found to undergo promoter methyla-
tion in lung cancer but not in the associated normal
lung. In a small series of 22 patients, the following
methylation frequencies were observed in NSCLC but
not in the normal lung tissue: p16 (41%), death-associ-
ated protein (DAP) kinase (23%), glutathione S trans-
ferase (GSTP1) (9%), MGMT (27%), or any of the
markers (68%).151 In addition, DNA containing these
methylated sequences could be detected in patients’
sera at the following frequencies when the tumors were
positive for the methylated marker: p16 (33%), DAP
kinase (80%), GSTP1 (50%), MGMT (66%), or any
marker (73%).151 Because the methylated DNA
sequences can be found even when they represent a
small fraction within total normal DNA, they are very
attractive candidates for early molecular detection tools
and for following chemoprevention studies. Other
regional sites of hypermethylation have been found in
lung cancer, including sites at 3p, 4q34, 10q26, and
17p13, although the precise gene targets at these sites
are uncertain and the significance is not yet appar-
ent.152,153 Methylation also plays a role in mediating
genomic imprinting, which is a gamete-specific modi-
fication causing differential expression of the two al-
leles of a gene. Loss of genomic imprinting of the IGF2
and H19 genes at 11p15 occurs in some lung cancers,
and in the case of IGF2 this could lead to IGF2 expres-
sion and lung cancer growth.154,155
Angiogenesis and metastases. Tumors cannot
exceed l- to 2-mm3 volume without new blood vessels
developing; thus they require angiogenic factors early
in their pathogenesis. Microvessel density may be
regarded as a morphologic measure of tumor angio-
genesis and has been variably linked to metastases and
impaired survival in lung cancer.156-159 Tumor angio-
genesis is complex and controlled by a diverse family
of inducers and inhibitors governing angiogenesis, reg-
ulating endothelial cell proliferation and migration.160
Vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor are among the more important
angiogenesis inducers. Expression of VEGF was asso-
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ciated with intratumoral microvessel density and tumor
cell proliferation in squamous lung cancer.161-163
Expression was higher in lung cancers with nodal
metastasis than in those without164 and was associated
with poor prognosis in NSCLC.162,165 In squamous cell
carcinomas, the VEGF receptor, Flt-1, is frequently
expressed, suggesting a possible autocrine role of
VEGF.165 Mutant p53 acts synergistically with hypoxia
to induce VEGF expression166 whereas wild-type p53
up-regulates the expression of the anti-angiogenic pro-
tein TSP-1.167 Basic fibroblast growth factor is
expressed in about 70% of NSCLCs, but its prognostic
significance is controversial.168,169 In addition, expres-
sion of the angiogenic platelet-derived endothelial cell
growth factor is correlated with tumor angiogenesis
and a worse prognosis in N0-stage NSCLCs.170
Angiogenic CXC chemokines such as interleukin 8
(IL-8) and epithelial neutrophil attractant 78 (ENA-78),
and angiostatic chemokines such as gamma interfer-
on–inducible protein 10 (IP-10), may also be relevant
in lung cancer.171 IL-8 may be an angiogenic factor for
SCLC, and IL-8 inhibition by passive immunization
reduces tumorigenesis of NSCLC xenografts in SCID
mice.172 In contrast, IP-10 was shown to inhibit
NSCLC tumorigenesis and spontaneous metastases.173
There are multiple new therapeutic strategies in lung
cancer directed against angiogenesis in general and
the VEGF system in particular. Currently, ongoing
clinical trials are testing a recombinant, “humanized,”
monoclonal antibody against VEGF (rhuMVEGF,
Genentech, Inc, South San Francisco, Calif) that blocks
the binding of VEGF to its receptor. The “humaniza-
tion” process takes a mouse monoclonal antibody and
replaces human sequences within it so that no immune
response is elicited when the antibody is given to
patients. Other preclinical studies or clinical trials
involve a monoclonal antibody directed against VEGF
receptor 2 (KDR/FLK1, ImClone Systems Incorpor-
ated, New York, NY), a tyrosine kinase inhibitor
(SU5416, SUGEN, Inc, South San Francisco, Calif),
and a ribozyme (Angiozyme) directed against the
VEGF receptor 1 (Flt-l) mRNA and thus inactivating
the receptor by inactivating the mRNA.
Tumor metastasis is a complex multistep host-depen-
dent process. Cell adhesion molecules have been impli-
cated in epithelial differentiation, carcinogenesis, and
metastasis. E-cadherin is responsible for the organiza-
tion, maintenance, and morphogenesis of epithelial tis-
sues, and reduced expression has been associated with
tumor dedifferentiation, increased lymphogenous
metastasis, and poor survival in NSCLC.174 The inte-
grins that bind to the major basement membrane com-
ponents (collagen and laminin) are down-regulated in
NSCLC.175 Reduced integrin a 3 expression is linked
with poor prognosis in adenocarcinomas.176 Others
have reported that the v6 isoform of the CD44 lympho-
cyte homing receptor correlates with adverse prognosis
in NSCLC.177 The degradation of the extracellular
matrix and basement membrane, particularly type IV
collagen, by tumor cells is essential for invasion and
metastasis. Type IV collagen expression of adenocarci-
nomas is progressively lost with increasing tumor de-
differentiation.178 The matrix metalloproteinase en-
zymes that degrade stroma and thus could lead to
tumor invasion and metastasis include collagenases,
gelatinases, stromelysins, membrane-type matrix me-
talloproteinases, matrilysin, and metalloelastase. Gel-
atinase A expression has been shown in both SCLCs
(~50%) and NSCLCs (~65%).179 The activation of
gelatinase A in lung cancer was correlated with mem-
brane-type matrix metalloproteinase mRNA expres-
sion, whose product is one of the pro-gelatinase activa-
tors.180 Stromelysin-3 has been shown to be more
strongly expressed by stromal elements in primary
NSCLCs than in adjacent normal lung specimens.181
Several drug companies have matrix metalloproteinase
inhibitors (Prinomastat from Agouron Pharmaceuti-
cals, Inc, [La Jolla, Calif] and BAY129566 from Bayer
AG [Leverkusen, Germany]) currently in clinical trials.
Molecular alterations in normal and preneoplastic
at-risk respiratory cells
The concept of cancers arising from precursor lesions
occurring in a multistep fashion has long been suggest-
ed and underpinned by the notion of somatically
acquired genetic alterations in preneoplastic cells,
which subsequently evolve into invasive cancer by
clonal expansion. Morphologically distinct preneoplas-
tic changes (hyperplasia, metaplasia, dysplasia, and
carcinoma in situ) can be observed in bronchial epithe-
lium before overt, invasive cancer develops. The
sequential morphologic changes that occur in preneo-
plastic lesions are better described for central squa-
mous cell carcinomas than for adenocarcinomas or
SCLCs. Some reversal of morphology can occur after
smoking cessation even though the elevated risk of
lung cancer does not completely return to baseline,
raising the possibility that there may be persistent areas
of at-risk bronchial epithelium, perhaps from being
irreversibly genetically altered. These preneoplastic
cells and even macroscopically normal bronchial
epithelium adjacent to cancers can contain genetic
abnormalities identical to those in invasive cancer cells.
These include allele loss at several loci (3p, 9p, 8p,
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17p), MYC and RAS up-regulation, cyclin D1 expres-
sion, p53 immunoreactivity, BCL-2 overexpression,
and DNA aneuploidy.182-186 Examination of microdis-
sected, preneoplastic lesions suggests that the earliest
change is allele loss at chromosome regions 3p, then
9p, 8p, 17p (with p53 mutation), 5q, and then RAS
mutations.187-190 However, topographic analyses by
others have indicated that KRAS activation also can
occur at early stages.185 Moreover, a potential precur-
sor lesion of adenocarcinomas, atypical alveolar hyper-
plasia, can also have KRAS mutations.39,191
Recent studies have suggested that the genetic
changes found in invasive cancers and preneoplasia can
also be identified in morphologically normal appearing
bronchial epithelium from current or former smok-
ers.190,192,193 In general, such genetic changes are not
found in the bronchial epithelium from true, lifetime
never smokers. The earliest change appearing in histo-
logically normal epithelium appears to be allele loss at
one of several different 3p sites. Approximately 50% of
histologically normal specimens from current or for-
mer smokers show 3p allele loss. There is also a pro-
gressive increase in the frequency and size of the areas
undergoing allele loss as the specimens progress from
normal, to hyperplasia or metaplasia (mildly abnor-
mal), to dysplasia, to carcinoma in situ.190,193 More-
over, some smokers exhibited allele loss at multiple
sites, a molecular picture frequently observed in carci-
noma in situ and invasive cancers.193
These observations are consistent with the multistep
model of carcinogenesis and a “field cancerization”
process, whereby the whole tissue region is repeatedly
exposed to carcinogenic damage (tobacco smoke) and
is at risk for the development of multiple, separate,
clonally unrelated foci of neoplasia. The widespread
aneuploidy that occurs throughout the respiratory tree
of smokers supports this notion.194 Interestingly, in
patients with lung cancer, geographically separate
regions of bronchial mucosa may demonstrate loss of
the same allele of a polymorphic marker (“allele-spe-
cific loss”). Although this could be consistent with a
clone populating a large part of the respiratory tree,
other mechanisms are not excluded.187,188 However, the
presence of the same somatic p53 gene point mutation
at widely dispersed preneoplastic lesions in a smoker
without invasive lung cancer is consistent with the
clonal expansion of a single progenitor clone through-
out the respiratory tree.195
Inherited lung cancer susceptibility
The major classes of carcinogens in tobacco smoke are
the polycyclic hydrocarbons (such as benzo[a]pyrene),
the nitrosamines, and the aromatic amines. Tobacco
smoke carcinogens may be activated enzymatically to
chemically reactive electrophiles that form carcinogen
DNA adducts. It has been hypothesized that an individ-
ual’s susceptibility to cancer may partially be affected by
the balance between the capacity to activate inhaled pro-
carcinogens (phase I enzymes) and the capacity to
detoxify carcinogens (phase II enzymes).196 It is increas-
ingly recognized that genetic polymorphisms common
in the population can affect each of these processes.
Thus an individual’s susceptibility to lung cancer could
be determined by these inherited factors coupled with
exposure through cigarette smoking. Familial factors
predisposing to lung cancer have long been suggest-
ed.197,198 The phenotypic variations that are thought to
be important in lung cancer include polymorphisms at
the P450 gene loci, such as CYP1A1, CYP2D6, and the
GST gene cluster.199,200 Early evidence suggests that dif-
ferent metabolic enzymes may be associated with tumor
subtype susceptibility to various tobacco smoke carcino-
gens.201 Another indication of individual variation was
the difference in the number of chromosome breaks in
peripheral blood lymphocytes after they were exposed in
vitro to benzo(a)pyrene diol-epoxide, a very carcino-
genic derivative of benzopyrene. Lung cancer cases and
controls had lymphocytes exposed to benzo(a)pyrene
diol-epoxide in vitro and then had the chromosomes
assayed by fluorescent in situ hybridization for deletions
in chromosome region 3p21.3. More deletions were
found in the lung cancer cases than in the controls such
that the phenotype of high numbers of 3p21.3 deletions
was associated with almost a 14-fold increase in risk of
having lung cancer.202 This could prove to be a very use-
ful marker for risk assessment of which individuals are
likely to have lung cancer develop. It also provides a cor-
relation between 3p deletions in the target tissue (lung)
compared with a surrogate tissue (lymphocytes) after
exposure to a respiratory carcinogen.
Clinical implications
We have given examples of how the new molecular
tools may change clinical practice in the future and
these are summarized in Table II. For instance, the
potential of molecular epidemiology is increasingly
recognized, with the aim of identifying individual
genetic susceptibility factors to lung cancer and indi-
viduals at the highest risk for the development of lung
cancer. This will be particularly important as we begin
large-scale spiral computed tomographic lung cancer
screening trials.203,204 Next, somatic mutational events
occur in airways exposed to tobacco smoke carcino-
gens and may lead to further refinement of risk predic-
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tion in genetically susceptible individuals. However,
any such molecular markers used for this and other
purposes such as intermediate markers for chemopre-
vention have to be tested and validated in prospective
clinical trials. Apart from this, early detection of lesions
remains a high priority for lung cancer workers,205 and
highly sensitive molecular methods are now able to
detect changes in one cancer cell among thousands.
Bodily fluids are suitable for molecular analysis, but
the challenge will be to identify a panel of markers that
are highly sensitive and specific for lung cancer.
Refinement of histologic diagnosis and categorization
of lung cancer subtypes may also be improved with
increasing knowledge of subtype-specific molecular
changes. Moreover, the molecular basis for tests such
as F-18 fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) scan may lead to more advanced
refinements in their use.206,207 We have also given
examples of some links to prognosis, but in general
most studies have until now been relatively small, ret-
rospective, and quite variable in methodology. Cur-
rently, there is no molecular marker that has major clin-
ical prognostic predictive value. Clinically valid
conclusions will need to come from large, adequately
powered prospective studies. Finally, there is much
therapeutic optimism for a variety of rationally based
new therapies. Thus, in the next millennium, the mole-
cular basis of lung cancer should provide us with the
new tools to counter the clinical nihilism that affects
lung cancer treatment. It is likely that these tools will
complement existing strategies for lung cancer control.
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